Skip to main content
Premium Trial:

Request an Annual Quote

UK Funds to Stay Ahead of Variants

The UK plans to spend an additional £29.3 million (US$40.7 million) on its effort to stay ahead of any SARS-CoV-2 viral variants, the Guardian reports.

This new funding comes on top of £19.7 million already promised to the UK's Porton Down facility, it adds. Currently, scientists at Porton Down are analyzing about 700 blood samples a week to gauge the effectiveness of SARS-CoV-2 vaccines against viral variants and plan to boost their testing capacity to 1,500 samples a week by January, the Guardian says. This infusion of new funding would enable them to double that capacity to 3,000.

In a statement, Matt Hancock, the health secretary, the new funding would "enable us to further future-proof the country from the threat of new variants."

The Financial Times notes that there are four variants of concern circulating in the UK and that existing vaccines provide some protection against them. Still, Sharon Peacock, the head of the COVID-19 Genomics UK consortium, tells it that "[looking] ahead, we need to study new variants very closely, particularly when the majority of the population have been vaccinated, and identify variants that could pose a greater threat to current vaccines."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.